Pancreatic cancer stands as one of the most formidable adversaries in the realm of oncology, with survival rates often tragically limited to mere months after diagnosis, highlighting the urgent need for innovative solutions. The relentless nature of this disease, coupled with its resistance to
Thyroid cancer, recognized as the most prevalent endocrine malignancy and ranking ninth among cancers globally, poses a significant health challenge with its diverse subtypes ranging from the more treatable papillary thyroid carcinoma to the highly aggressive anaplastic thyroid carcinoma, each
Today, we’re thrilled to sit down with Ivan Kairatov, a renowned expert in biopharmaceuticals with a deep focus on technology and innovation in the industry. With extensive experience in research and development, Ivan has been at the forefront of advancing cancer treatments, particularly in the
Neuroblastoma, a devastating cancer affecting primarily children under five, stands as one of the most aggressive solid tumors in pediatric populations, with high-risk cases often showing dismal outcomes despite rigorous treatments. With only about half of these young patients achieving a cure
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert whose extensive experience in research and development, coupled with a keen understanding of tech and innovation, has positioned him at the forefront of groundbreaking advancements in cancer treatment. Today, we’re diving into
The biotechnology sector often rides a rollercoaster of high hopes and sharp setbacks, and few cases illustrate this better than the recent plunge in Exelixis’ stock value following the release of data from its STELLAR-303 trial. Focused on zanzalintinib, an experimental drug for metastatic
